Philadelphia-based biotech firm Vivodyne has successfully closed a $38 million seed funding round led by Khosla Ventures, with participation from CS Ventures, Kairos Ventures, Bison Ventures, and MBX Capital.
Vivodyne specialises in AI-driven drug discovery, using clinically predictive AI to identify therapeutic targets and predict patient responses by testing on lab-grown human organ tissues. The company's robotic automation allows it to manage over 10,000 lab-grown human organ tissues simultaneously, generating extensive datasets crucial for training AI algorithms. The funds will advance both Vivodyne's drug discovery pipeline and its AI stack.
According to Alex Morgan of Khosla Ventures, Vivodyne's technology fills the gap between preclinical research and human clinical trials, improving success rates. The automated platform manages the entire testing pipeline, offering a significant leap forward for the pharmaceutical industry.
In the broader context of AI in drug discovery, the increasing use of open-source databases and AI-based software is noted, emphasising the necessity for collaboration across disciplines to ensure effective synergy between human expertise and machine capabilities. The article also highlights other players in the AI-driven drug discovery landscape, such as California-based startup Genesis and Israel-based AION Labs, showcasing the industry's collaborative and innovative nature.
Click here to read the original news story.